{"pmid":32458546,"title":"Cutaneous manifestations of COVID-19: A review of the published literature.","text":["Cutaneous manifestations of COVID-19: A review of the published literature.","COVID-19 is a highly contagious respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). COVID-19 outbreak, which caused thousands of deaths, has been declared a pandemic by the World Health Organization in March 2020. The infection has been reported to demonstrate different types of cutaneous manifestations including urticarial, maculopapular, papulovesicular, purpuric, livedoid, and thromboticischemic lesions. Given the high mortality rate of the infection, timely and accurate identification of relevant cutaneous manifestations may play a key role in the early diagnosis and management. In this study, we provide a review with a focus on the reported cutaneous manifestations of COVID-19. This article is protected by copyright. All rights reserved.","Dermatol Ther","Elmas, Omer Faruk","Demirbas, Abdullah","Ozyurt, Kemal","Atasoy, Mustafa","Tursen, Umit","32458546"],"abstract":["COVID-19 is a highly contagious respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). COVID-19 outbreak, which caused thousands of deaths, has been declared a pandemic by the World Health Organization in March 2020. The infection has been reported to demonstrate different types of cutaneous manifestations including urticarial, maculopapular, papulovesicular, purpuric, livedoid, and thromboticischemic lesions. Given the high mortality rate of the infection, timely and accurate identification of relevant cutaneous manifestations may play a key role in the early diagnosis and management. In this study, we provide a review with a focus on the reported cutaneous manifestations of COVID-19. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Elmas, Omer Faruk","Demirbas, Abdullah","Ozyurt, Kemal","Atasoy, Mustafa","Tursen, Umit"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458546","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13696","keywords":["covid-19","coronavirus","cutaneous manifestations","skin"],"topics":["Diagnosis"],"weight":1,"_version_":1667967698869420032,"score":9.490897,"similar":[{"pmid":32381430,"pmcid":"PMC7189855","title":"Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.","text":["Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.","BACKGROUND: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, overall similarities in the clinical presentation of these dermatological manifestations have not yet been summarized. OBJECTIVE: This review aims to provide an overview of various cutaneous manifestations in patients with COVID-19 through three case reports and a literature review. METHODS: A literature search was conducted using PubMed, OVID, and Google search engines for original and review articles. Studies written in the English language that mentioned cutaneous symptoms and COVID-19 were included. RESULTS: Eighteen articles and three additional cases reported in this paper were included in this review. Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1% (26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72), urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions (2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72), however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5% (9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the studies reported no correlation between COVID-19 severity and skin lesions. CONCLUSION: Infection with COVID-19 may result in dermatological manifestations with various clinical presentations, which may aid in the timely diagnosis of this infection.","J Dermatol Sci","Sachdeva, Muskaan","Gianotti, Raffaele","Shah, Monica","Lucia, Bradanini","Tosi, Diego","Veraldi, Stefano","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P","32381430"],"abstract":["BACKGROUND: Various cutaneous manifestations have been observed in patients with COVID-19 infection. However, overall similarities in the clinical presentation of these dermatological manifestations have not yet been summarized. OBJECTIVE: This review aims to provide an overview of various cutaneous manifestations in patients with COVID-19 through three case reports and a literature review. METHODS: A literature search was conducted using PubMed, OVID, and Google search engines for original and review articles. Studies written in the English language that mentioned cutaneous symptoms and COVID-19 were included. RESULTS: Eighteen articles and three additional cases reported in this paper were included in this review. Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1% (26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72), urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions (2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72), however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5% (9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the studies reported no correlation between COVID-19 severity and skin lesions. CONCLUSION: Infection with COVID-19 may result in dermatological manifestations with various clinical presentations, which may aid in the timely diagnosis of this infection."],"journal":"J Dermatol Sci","authors":["Sachdeva, Muskaan","Gianotti, Raffaele","Shah, Monica","Lucia, Bradanini","Tosi, Diego","Veraldi, Stefano","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381430","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jdermsci.2020.04.011","keywords":["covid-19","cutaneous manifestations","review","skin"],"topics":["Case Report"],"weight":1,"_version_":1666419683361816576,"score":338.71765},{"pmid":32383234,"title":"Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","text":["Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): a brief review.","COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved.","Dermatol Ther","Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning","32383234"],"abstract":["COVID-19, first appeared in December 2019 in Wuhan, China, has been spreading quickly throughout the world. We reviewed the evidence on cutaneous manifestations of COVID-19 based on PubMed database. The searching strategy was (COVID* or coronavirus*) and (dermatol* or skin* or cutaneous*). The publication time was limited to 2019 onward. After independent review by two authors, 14 studies with 228 confirmed cases were included in the analysis. A total of 60 patients developed skin rashes, and the age ranged from 8 to 84. Exanthematous eruptions potentially related to COVID-19 infection were highly variable and heterogeneous. Skin lesions mainly appeared erythematous, urticarial, and vesicular (chicken pox-like or varicelliform). Petechiae rash, livedo reticularis, and reactivation of oral HSV-1 were also observed in single cases. Newly reported eruptions like vascular lesions and peculiar (perniosis-like) skin lesions caused concern among dermatologists. Exanthems were widely distributed and were primarily located on the trunk. Associated symptoms, latency time, treatment, and prognosis were also carefully summarized. This study reviewed the recently published COVID-19 studies with skin manifestations, which may pave the way for further research. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Tang, Keyun","Wang, Yuanzhuo","Zhang, Hanlin","Zheng, Qingyue","Fang, Rouyu","Sun, Qiuning"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32383234","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/dth.13528","keywords":["covid-19","coronavirus","cutaneous manifestations","review","skin"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666267276793348098,"score":298.31998},{"pmid":32479680,"title":"Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue.","text":["Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue.","BACKGROUND: The infection caused by the recently identified SARS-CoV-2, called COronaVIrus Disease-19 (COVID-19), has rapidly spread throughout the world. With the exponential increase of patients worldwide, the clinical spectrum of COVID-19 is being better defined and new symptoms are emerging. Numerous reports are documenting the occurrence of different cutaneous manifestations in COVID-19 patients. OBJECTIVES: To provide a brief overview of the COVID-19-associated cutaneous lesions. METHODS: Literature search was performed in the PubMed, Scopus and Web of Science databases up to 30 April 2020. This narrative review summarizes the available data regarding clinical and histological features of COVID-19-associated skin manifestations. RESULTS: Literature reports showed a great heterogeneity in COVID-19-associated cutaneous manifestations, as well as in their latency periods and associated extracutaneous symptoms. Pathogenic mechanisms are unknown, although the role of hyperactive immune response, complement activation and microvascular injury has been hypothesized. Based on our experience and the literature data, we subdivided the reported cutaneous lesions into six main clinical patterns: i) urticarial rash, ii) confluent erythematous/maculo-papular/morbilliform rash, iii) papulovesicular exanthem, iv) chilblain-like acral pattern, v) livedo reticularis/racemosa-like pattern, vi) purpuric \"vasculitic\" pattern. These six patterns can be merged into two main settings: the first one - inflammatory/exanthematous - including the first three groups cited above and the second one including the vasculopathic/vasculitic lesions of the last three aforementioned groups. CONCLUSIONS: The possible presence of cutaneous findings leading to suspect COVID-19 puts dermatologists in a relevant position. Further studies are needed to delineate the diagnostic and prognostic value of such cutaneous manifestations.","Br J Dermatol","Marzano, A V","Cassano, N","Genovese, G","Moltrasio, C","Vena, G A","32479680"],"abstract":["BACKGROUND: The infection caused by the recently identified SARS-CoV-2, called COronaVIrus Disease-19 (COVID-19), has rapidly spread throughout the world. With the exponential increase of patients worldwide, the clinical spectrum of COVID-19 is being better defined and new symptoms are emerging. Numerous reports are documenting the occurrence of different cutaneous manifestations in COVID-19 patients. OBJECTIVES: To provide a brief overview of the COVID-19-associated cutaneous lesions. METHODS: Literature search was performed in the PubMed, Scopus and Web of Science databases up to 30 April 2020. This narrative review summarizes the available data regarding clinical and histological features of COVID-19-associated skin manifestations. RESULTS: Literature reports showed a great heterogeneity in COVID-19-associated cutaneous manifestations, as well as in their latency periods and associated extracutaneous symptoms. Pathogenic mechanisms are unknown, although the role of hyperactive immune response, complement activation and microvascular injury has been hypothesized. Based on our experience and the literature data, we subdivided the reported cutaneous lesions into six main clinical patterns: i) urticarial rash, ii) confluent erythematous/maculo-papular/morbilliform rash, iii) papulovesicular exanthem, iv) chilblain-like acral pattern, v) livedo reticularis/racemosa-like pattern, vi) purpuric \"vasculitic\" pattern. These six patterns can be merged into two main settings: the first one - inflammatory/exanthematous - including the first three groups cited above and the second one including the vasculopathic/vasculitic lesions of the last three aforementioned groups. CONCLUSIONS: The possible presence of cutaneous findings leading to suspect COVID-19 puts dermatologists in a relevant position. Further studies are needed to delineate the diagnostic and prognostic value of such cutaneous manifestations."],"journal":"Br J Dermatol","authors":["Marzano, A V","Cassano, N","Genovese, G","Moltrasio, C","Vena, G A"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479680","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjd.19264","topics":["Diagnosis"],"weight":1,"_version_":1668532089570459648,"score":273.20352},{"pmid":32314436,"title":"Comment on \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S.","text":["Comment on \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S.","Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), patients with COVID-19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S. (5).","J Eur Acad Dermatol Venereol","Hedou, M","Carsuzaa, F","Chary, E","Hainaut, E","Cazenave-Roblot, F","Masson Regnault, M","32314436"],"abstract":["Since the coronavirus disease 2019 (COVID 19) outbreak was first reported in the Chinese city of Wuhan on December 31, 2019, it has stricken more than 1,000,000 persons worldwide, of whom over 50,000 have died (1). Having been infected by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), patients with COVID-19 mainly present with fever and respiratory symptoms (2). Isolated sudden onset anosmia has also frequently been reported (3). Less frequently, rhinorrhea, diarrhoea and dysgeusia may be associated. While only a few reports have evoked cutaneous manifestations (4), we read with interest an initial study on the topic entitled \"Cutaneous manifestations in COVID-19: a first perspective \" by Recalcati S. (5)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Hedou, M","Carsuzaa, F","Chary, E","Hainaut, E","Cazenave-Roblot, F","Masson Regnault, M"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314436","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16519","keywords":["covid-19 infections","cutaneous manifestations","skin"],"locations":["Chinese","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493420568576,"score":237.38971},{"pmid":32348545,"title":"Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.","text":["Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.","BACKGROUND: Cutaneous manifestations of COVID-19 disease are poorly characterized. OBJECTIVES: To describe the cutaneous manifestations of COVID-19 disease and to relate them to other clinical findings METHODS: Nationwide case collection survey of images and clinical data. Using a consensus, we described 5 clinical patterns. We later described the association of these patterns with patient demographics, timing in relation to symptoms of the disease, severity, and prognosis. RESULTS: Lesions may be classified as acral areas of erythema with vesicles or pustules (Pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID-19. Severity of COVID-19 shows a gradient from less severe disease in acral lesions to most severe in the latter groups. Results are similar for confirmed and suspected cases, both in terms of clinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo-chilblain and vesicular). CONCLUSIONS: We provide a description of the cutaneous manifestations associated with COVID-19 infection. These may help clinicians approach patients with the disease and recognize paucisymptomatic cases.","Br J Dermatol","Galvan Casas, C","Catala, A","Carretero Hernandez, G","Rodriguez-Jimenez, P","Fernandez Nieto, D","Rodriguez-Villa Lario, A","Navarro Fernandez, I","Ruiz-Villaverde, R","Falkenhain, D","Llamas Velasco, M","Garcia-Gavin, J","Baniandres, O","Gonzalez-Cruz, C","Morillas-Lahuerta, V","Cubiro, X","Figueras Nart, I","Selda-Enriquez, G","Romani, J","Fusta-Novell, X","Melian-Olivera, A","Roncero Riesco, M","Burgos-Blasco, P","Sola Ortigosa, J","Feito Rodriguez, M","Garcia-Doval, I","32348545"],"abstract":["BACKGROUND: Cutaneous manifestations of COVID-19 disease are poorly characterized. OBJECTIVES: To describe the cutaneous manifestations of COVID-19 disease and to relate them to other clinical findings METHODS: Nationwide case collection survey of images and clinical data. Using a consensus, we described 5 clinical patterns. We later described the association of these patterns with patient demographics, timing in relation to symptoms of the disease, severity, and prognosis. RESULTS: Lesions may be classified as acral areas of erythema with vesicles or pustules (Pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID-19. Severity of COVID-19 shows a gradient from less severe disease in acral lesions to most severe in the latter groups. Results are similar for confirmed and suspected cases, both in terms of clinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo-chilblain and vesicular). CONCLUSIONS: We provide a description of the cutaneous manifestations associated with COVID-19 infection. These may help clinicians approach patients with the disease and recognize paucisymptomatic cases."],"journal":"Br J Dermatol","authors":["Galvan Casas, C","Catala, A","Carretero Hernandez, G","Rodriguez-Jimenez, P","Fernandez Nieto, D","Rodriguez-Villa Lario, A","Navarro Fernandez, I","Ruiz-Villaverde, R","Falkenhain, D","Llamas Velasco, M","Garcia-Gavin, J","Baniandres, O","Gonzalez-Cruz, C","Morillas-Lahuerta, V","Cubiro, X","Figueras Nart, I","Selda-Enriquez, G","Romani, J","Fusta-Novell, X","Melian-Olivera, A","Roncero Riesco, M","Burgos-Blasco, P","Sola Ortigosa, J","Feito Rodriguez, M","Garcia-Doval, I"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348545","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/bjd.19163","keywords":["covid-19","skin manifestations","diagnosis"],"locations":["Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495413911552,"score":212.50407}]}